These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 22065948)

  • 21. Molecular mechanisms of psychostimulant addiction.
    Chen JC; Chen PC; Chiang YC
    Chang Gung Med J; 2009; 32(2):148-54. PubMed ID: 19403004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bitropic D3 Dopamine Receptor Selective Compounds as Potential Antipsychotics.
    Luedtke RR; Rangel-Barajas C; Malik M; Reichert DE; Mach RH
    Curr Pharm Des; 2015; 21(26):3700-24. PubMed ID: 26205291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycogen Synthase Kinase-3 is an Intermediate Modulator of Serotonin Neurotransmission.
    Polter AM; Li X
    Front Mol Neurosci; 2011; 4():31. PubMed ID: 22028682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopamine D
    Chang PK; Chu J; Tsai YT; Lai YH; Chen JC
    J Biomed Sci; 2020 Jan; 27(1):16. PubMed ID: 31900153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective disruption of dopamine D2-receptors/beta-arrestin2 signaling by mood stabilizers.
    Del' Guidice T; Beaulieu JM
    J Recept Signal Transduct Res; 2015 Jun; 35(3):224-32. PubMed ID: 26459714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
    Morissette M; Samadi P; Hadj Tahar A; Bélanger N; Di Paolo T
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):446-54. PubMed ID: 20026151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics.
    Masri B; Salahpour A; Didriksen M; Ghisi V; Beaulieu JM; Gainetdinov RR; Caron MG
    Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13656-61. PubMed ID: 18768802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An emerging role for Wnt and GSK3 signaling pathways in schizophrenia.
    Singh KK
    Clin Genet; 2013 Jun; 83(6):511-7. PubMed ID: 23379509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. G protein-coupled receptor kinases as regulators of dopamine receptor functions.
    Gurevich EV; Gainetdinov RR; Gurevich VV
    Pharmacol Res; 2016 Sep; 111():1-16. PubMed ID: 27178731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins.
    de Bartolomeis A; Buonaguro EF; Iasevoli F
    Psychopharmacology (Berl); 2013 Jan; 225(1):1-19. PubMed ID: 23179966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade.
    Beaulieu JM; Sotnikova TD; Yao WD; Kockeritz L; Woodgett JR; Gainetdinov RR; Caron MG
    Proc Natl Acad Sci U S A; 2004 Apr; 101(14):5099-104. PubMed ID: 15044694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopamine D3 receptor deletion increases tissue plasminogen activator (tPA) activity in prefrontal cortex and hippocampus.
    Castorina A; D'Amico AG; Scuderi S; Leggio GM; Drago F; D'Agata V
    Neuroscience; 2013 Oct; 250():546-56. PubMed ID: 23906635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopamine receptors - IUPHAR Review 13.
    Beaulieu JM; Espinoza S; Gainetdinov RR
    Br J Pharmacol; 2015 Jan; 172(1):1-23. PubMed ID: 25671228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel Insight to Neuroprotective Potential of Curcumin: A Mechanistic Review of Possible Involvement of Mitochondrial Biogenesis and PI3/Akt/ GSK3 or PI3/Akt/CREB/BDNF Signaling Pathways.
    Kandezi N; Mohammadi M; Ghaffari M; Gholami M; Motaghinejad M; Safari S
    Int J Mol Cell Med; 2020; 9(1):1-32. PubMed ID: 32832482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine D1 receptor activation induces tau phosphorylation via cdk5 and GSK3 signaling pathways.
    Lebel M; Patenaude C; Allyson J; Massicotte G; Cyr M
    Neuropharmacology; 2009 Sep; 57(4):392-402. PubMed ID: 19591849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.
    Beurel E; Grieco SF; Jope RS
    Pharmacol Ther; 2015 Apr; 148():114-31. PubMed ID: 25435019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AKT/GSK3 signaling pathway and schizophrenia.
    Emamian ES
    Front Mol Neurosci; 2012; 5():33. PubMed ID: 22435049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postsynaptic D2 dopamine receptor supersensitivity in the striatum of mice lacking TAAR1.
    Espinoza S; Ghisi V; Emanuele M; Leo D; Sukhanov I; Sotnikova TD; Chieregatti E; Gainetdinov RR
    Neuropharmacology; 2015 Jun; 93():308-13. PubMed ID: 25721394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Critical Impact of Different Conserved Endoplasmic Retention Motifs and Dopamine Receptor Interacting Proteins (DRIPs) on Intracellular Localization and Trafficking of the D
    Blagotinšek Cokan K; Mavri M; Rutland CS; Glišić S; Senćanski M; Vrecl M; Kubale V
    Biomolecules; 2020 Sep; 10(10):. PubMed ID: 32977535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anaplastic Lymphoma Kinase Regulates Internalization of the Dopamine D2 Receptor.
    He D; Lasek AW
    Mol Pharmacol; 2020 Feb; 97(2):123-131. PubMed ID: 31734646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.